Nurix Therapeutics, Inc. NRIX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Nurix Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s return on equity?
- Nurix Therapeutics, Inc. (NRIX) reported return on equity of -61.4% in Q4 2025.
- How has Nurix Therapeutics, Inc.'s return on equity changed year-over-year?
- Nurix Therapeutics, Inc.'s return on equity increased by 4.3% year-over-year, from -64.2% to -61.4%.
- What is the long-term trend for Nurix Therapeutics, Inc.'s return on equity?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s return on equity has grown at a 7.6% compound annual growth rate (CAGR), from -37.1% to -49.6%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.